Research Paper Volume 14, Issue 22 pp 9000—9019

NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway

Rui Zhao1,2, , Yuzhen Ge1, , Yongjun Gong2, , Bo Li1, , Benli Xiao1, , Shi Zuo1,2, ,

  • 1 Guizhou Medical University, Guiyang, Guizhou 550001, China
  • 2 Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550001, China

Received: September 26, 2022       Accepted: October 29, 2022       Published: November 11, 2022
How to Cite

Copyright: © 2022 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. Nucleosome assembly protein 1-like 5 (NAP1L5) is a protein-coding gene that encodes a protein similar to nucleosome assembly protein 1 (NAP1). It is a histone chaperone that plays an important role in gene transcription in organisms. However, the role of NAP1L5 in the pathogenesis of hepatocellular carcinoma remains to be elucidated. In this study, low expression of NAP1L5 was found in hepatocellular carcinoma, and the downregulation of NAP1L5 was related to shorter survival and disease-free survival. In addition, its expression is also related to the tumor size and recurrence of hepatocellular carcinoma. The overexpression and knockdown of NAP1L5 by plasmid and siRNA showed that NAP1L5 inhibited the proliferation, migration and invasion and induced apoptosis of hepatoma cells. In vivo experiments confirmed that NAP1L5 can inhibit the growth and metastasis of hepatocellular carcinoma cells. In the mechanistic study, we found that NAP1L5 affects the occurrence and development of hepatocellular carcinoma by regulating MYH9 to inhibit the PI3K/AKT/mTOR signaling pathway. As a functional tumor suppressor, NAP1L5 is expressed at low levels in HCC. NAP1L5 inhibits the PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma by regulating MYH9. It may be a new potential target for liver cancer treatment.


HCC: Hepatocellular carcinoma; NAP1: Nucleosome assembly protein 1; NAP1L5: Nucleosome assembly protein 1- like 5; IHC: Immunohistochemistry; Co-IP: Coimmunoprecipitation; EMT: Epithelial–mesenchymal transition; CAMP: Cyclic adenosine monophosphate; SREBP-1: Sterol regulatory element binding protein-1; MYH9-RD: MYH9-related diseases.